Evidence map›Paper›PMID 35345541›Full record

ArticlePatient preference and adherence2022

Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis.

Ashley J Housten, Catalina Malinowski, Edna Paredes, Cassandra L Harris, Lorna H McNeill, Mariana Chavez-MacGregor

Open access · goldAbstract read
In one paragraph

Article in Patient preference and adherence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Culturally appropriate patient-provider communication methods for Black women with breast cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ashley J HoustenDivision of Public Health Sciences, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-7379-0678
Catalina MalinowskiDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8069-541X
Edna ParedesDepartment of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2832-9751
Cassandra L HarrisDepartment of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7098-5023
Lorna H McNeillDepartment of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1594-6301
Mariana Chavez-MacGregorDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7189-0763
The University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Breast Cancer Screening: Priorities and Attitudes of Diverse Women Under 50R00MD011485 · NIMHD · WASHINGTON UNIVERSITY · PI HOUSTEN, ASHLEY · 2019 to 2021
$712k
NCI NIH HHS P30 CA016672NIMHD NIH HHS R00 MD011485
6 · The paper itself

Abstract

Purpose: (Neo) adjuvant chemotherapy decreases the risk of recurrence and improves overall survival among breast cancer patients; however, delays in chemotherapy initiation are associated with adverse health outcomes. The causes of delay are complex and include interrelated social, economic, cultural, environmental, and health system factors. Project Start was a qualitative study designed to assess and identify the multilevel factors contributing to the barriers and facilitators of initiating chemotherapy. Patients and Methods: Women diagnosed with primary invasive breast cancer who experienced ≥60 day delay in (neo) adjuvant chemotherapy initiation were included. Participants completed semi-structured interviews exploring barriers and facilitators to starting chemotherapy. Interviews were transcribed and coded to identify themes using the Results: We enrolled (N=22) participants with median age at diagnosis 53.5 years (range 27-70) who identified as Latina (n=8), Black (n=5), and non-Latina White (n=9). Participants described a common chemotherapy initiation process reflecting their unique needs as they transitioned through four stages: 1) receiving diagnosis and treatment recommendations; 2) processing treatment options; 3) "Flipping the Switch"; and 4) activating treatment and engaging in care. Limited explicit insight into their chemotherapy delay was expressed. Engagement across the self-, family-, community-, and medical-realms revealed interlinked and pivotal sources of support that helped participants navigate toward initiating chemotherapy. Specifically, the overarching themes included logistical, emotional, financial, and social sources of support and the relationship of these sources of support to participants' perceived self-efficacy to move toward initiating treatment. Conclusion: Activating women to be engaged in the treatment process across multiple levels appeared to facilitate initiating chemotherapy. Multilevel interventions that engage the patient, family, community, and medical team may support the initiation of timely chemotherapy.

Indexed as

breast cancercare deliverychemotherapyoncologypatient perspectivesqualitativetreatment delay

Identifiers

PMID35345541
PMCPMC8957340
OpenAlexW4220730243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.